

Bourne Partners Advises The Carlyle Group on Acquisition of AMRI

Albany, N.Y. – Albany Molecular Research, Inc. (NASDAQ: AMRI), a contract research and manufacturing organization, announced that it has signed a definitive agreement to be acquired by affiliates of The Carlyle Group (“Carlyle”), as well as GTCR LLC (“GTCR”), for \$21.75 per share in cash.

AMRI’s Board of Directors unanimously approved the agreement, and recommended the shareholders to vote in favor of the deal. It is anticipated that the shareholders will vote on the transaction within the third quarter of 2017. If the transaction is approved, the merger is expected to close shortly thereafter.

Through their joint venture, Bourne Partners (“Bourne”) has worked alongside The Carlyle Group since January 2016, advising on various pharma and pharma services investments, including the AMRI transaction. Additionally, Bourne Partners has invested in, built and advised numerous specialty pharmaceutical companies over the last decade. As advisors, investors and operators, Bourne has been involved with transactions ranging from \$10 million to more than \$3 billion.

Stephen H. Wise, Managing Director and Global Head of Healthcare for Carlyle, said, “Banks, Minor, Jeremy and the Bourne team worked diligently and added value in the evaluation and negotiation phases of the AMRI transaction. Their insight, experience and understanding of the CDMO and pharmaceutical sectors proved extremely useful and insightful. We also look forward to their investment and involvement alongside Carlyle in AMRI’s future growth strategy.”

Banks Bourne, Founder and Chief Executive Officer of Bourne Partners, said, “Bourne Partners was pleased to provide its expertise in the CDMO and pharma space to Carlyle in its pending acquisition of AMRI. We believe AMRI is an attractive, established contract services platform from which to pursue investment opportunities in the pharma services and products industry. We look forward to providing continued advisory support to and investing alongside the Healthcare team at Carlyle. We are equally excited to begin working with the executive team at AMRI and contributing to their continued success as a preeminent CDMO.”

About AMRI

Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working in with the life sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, key business segments include

Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP), and Fine Chemicals (FC). For more information about AMRI, please visit www.amriglobal.com or follow on Twitter ([@amriglobal](https://twitter.com/amriglobal)).

About The Carlyle Group

The Carlyle Group (NASDAQ: CG) is a global alternative asset manager with \$188 billion of assets under management across 126 funds and 160 fund of funds vehicles. Carlyle's purpose is to invest wisely and create value on behalf of its investors, many of whom are public pensions. Carlyle invests across four segments – Corporate Private Equity, Real Assets, Global Market Strategies and Investment Solutions – in *Africa, Asia, Australia, Europe, the Middle East, North America and South America*. Carlyle has expertise in various industries, including: aerospace, defense & government services, consumer & retail, energy, financial services, healthcare, industrial, real estate, technology & business services, telecommunications & media and transportation. The Carlyle Group employs more than 1,700 people in 35 offices across six continents.

About GTCR

Founded in 1980, GTCR is a leading private equity firm focused on investing in growth companies in the Financial Services & Technology, Healthcare, Technology, Media & Telecommunications and Growth Business Services industries. The Chicago-based firm pioneered The Leaders Strategy™ - finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through transformational acquisitions and organic growth. Since its inception, GTCR has invested more than \$12 billion in over 200 companies. For more information, please visit www.gtcr.com.

About Bourne Partners

Bourne Partners is a financial services firm specializing in the pharma, pharma services and consumer health sectors. Located in Charlotte, North Carolina, the company offers investment banking and advisory services, as well as direct investment opportunities. As owners and operators with over 15 years of experience, Bourne Partners strives to enrich the lives and improve the health and well-being of their partners and patients across the globe by facilitating the efficient movement of capital through the global healthcare sector. For more information, please visit www.bourne-partners.com.